Crizotinib

Neoplasms

Hoffmann-La RocheSmall moleculePhase 3Dormant

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 57/ 100
Competitive Position: 65/ 100

Competitive context

928 Active assets in the Neoplasms cohort.

Asset / Sponsor	Phase	Rating
PANITUMUMAB Astellas Pharma Inc	Phase 2	BBB
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM Sanofi	Phase 4	BB
Inno-206 The First Affiliated Hospital of Soochow University	Phase 2/3	BB
DINITROGEN MONOXIDE Medical College of Wisconsin	Phase 4	BB
Glycopyrrolate Medical College of Wisconsin	Phase 4	BB

View all 50 →

Same molecule, other indications

Crizotinib is also rated in:

anaplastic large cell lymphomaDormant

BBB

Indicative ·

75 / 100

inflammatory myofibroblastic tumorDormant

BB

Indicative ·

69 / 100

ALK-positive anaplastic large cell lymphomaDormant

BB

Indicative ·

68 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.